Cargando…

TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies

SIMPLE SUMMARY: Therapies targeting TIGIT have garnered tremendous interest, but have so far failed to reach primary endpoints in PhIII trials in lung cancer settings. This study examined the function of TIGIT on NK cells and how NK cells may impact the success of TIGIT therapeutics. This study demo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasan, Md Faqrul, Croom-Perez, Tayler J., Oyer, Jeremiah L., Dieffenthaller, Thomas A., Robles-Carrillo, Liza D., Eloriaga, Jonathan E., Kumar, Sanjana, Andersen, Brendan W., Copik, Alicja J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216728/ https://www.ncbi.nlm.nih.gov/pubmed/37345049 http://dx.doi.org/10.3390/cancers15102712

Ejemplares similares

Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo
por: Oyer, Jeremiah L., et al.
Publicado: (2022)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
por: Meng, Fanqiao, et al.
Publicado: (2020)

Anti-TIGIT therapies for solid tumors: a systematic review
por: Rousseau, A., et al.
Publicado: (2023)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4(+) T cells
por: Holder, Kayla A, et al.
Publicado: (2021)

TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
por: Tsakmaklis, Anastasia, et al.
Publicado: (2023)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma
por: Lupo, Kyle B., et al.
Publicado: (2023)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

TIGIT in Lung Cancer: Potential Theranostic Implications
por: Pescia, Carlo, et al.
Publicado: (2023)

Studying TIGIT activity against tumors through the generation of knockout mice
por: Rishiq, Ahmed, et al.
Publicado: (2023)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
por: Ge, Zhouhong, et al.
Publicado: (2021)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling
por: Varudkar, Namita, et al.
Publicado: (2021)

The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells
por: Ziegler, Annerose E., et al.
Publicado: (2023)

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
por: Blessin, Niclas C., et al.
Publicado: (2019)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

TIGIT limits immune pathology during viral infections
por: Schorer, Michelle, et al.
Publicado: (2020)

Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
por: Lucca, Liliana E., et al.
Publicado: (2020)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

Discovery of TIGIT inhibitors based on DEL and machine learning
por: Xiong, Feng, et al.
Publicado: (2022)

Expression and Clinical Significance of TIGIT in Primary Breast Cancer
por: Tang, Limin, et al.
Publicado: (2023)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals
por: Yin, Xiaowan, et al.
Publicado: (2018)

Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells
por: Varudkar, Namita, et al.
Publicado: (2023)

PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
por: Fu, Zhihao, et al.
Publicado: (2021)

TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir
por: Holder, Kayla A., et al.
Publicado: (2020)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4t3m0nfkrq4fiopma97gu59jlo